1567 related articles for article (PubMed ID: 28530702)
21. Metformin and gut microbiota: their interactions and their impact on diabetes.
Vallianou NG; Stratigou T; Tsagarakis S
Hormones (Athens); 2019 Jun; 18(2):141-144. PubMed ID: 30719628
[TBL] [Abstract][Full Text] [Related]
22. Response of gut microbiota in type 2 diabetes to hypoglycemic agents.
Zhang F; Wang M; Yang J; Xu Q; Liang C; Chen B; Zhang J; Yang Y; Wang H; Shang Y; Wang Y; Mu X; Zhu D; Zhang C; Yao M; Zhang L
Endocrine; 2019 Dec; 66(3):485-493. PubMed ID: 31410749
[TBL] [Abstract][Full Text] [Related]
23. Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India.
Alvarez-Silva C; Kashani A; Hansen TH; Pinna NK; Anjana RM; Dutta A; Saxena S; Støy J; Kampmann U; Nielsen T; Jørgensen T; Gnanaprakash V; Gnanavadivel R; Sukumaran A; Rani CSS; Færch K; Radha V; Balasubramanyam M; Nair GB; Das B; Vestergaard H; Hansen T; Mande SS; Mohan V; Arumugam M; Pedersen O
Genome Med; 2021 Mar; 13(1):37. PubMed ID: 33658058
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the gut microbiota after metformin intervention in children with obesity: A metagenomic study of a randomized controlled trial.
Pastor-Villaescusa B; Plaza-Díaz J; Egea-Zorrilla A; Leis R; Bueno G; Hoyos R; Vázquez-Cobela R; Latorre M; Cañete MD; Caballero-Villarraso J; Gil Á; Cañete R; Aguilera CM
Biomed Pharmacother; 2021 Feb; 134():111117. PubMed ID: 33360047
[TBL] [Abstract][Full Text] [Related]
25. Gut microbiome encoded purine and amino acid pathways present prospective biomarkers for predicting metformin therapy efficacy in newly diagnosed T2D patients.
Elbere I; Orlovskis Z; Ansone L; Silamikelis I; Jagare L; Birzniece L; Megnis K; Leskovskis K; Vaska A; Turks M; Klavins K; Pirags V; Briviba M; Klovins J
Gut Microbes; 2024; 16(1):2361491. PubMed ID: 38868903
[TBL] [Abstract][Full Text] [Related]
26. Changes in the type 2 diabetes gut mycobiome associate with metformin treatment across populations.
Van Syoc E; Nixon MP; Silverman JD; Luo Y; Gonzalez FJ; Elbere I; Klovins J; Patterson AD; Rogers CJ; Ganda E
mBio; 2024 Jun; 15(6):e0016924. PubMed ID: 38767350
[TBL] [Abstract][Full Text] [Related]
27. Metformin Reduces Blood Glucose in Treatment-Naive Type 2 Diabetes by Altering the Gut Microbiome.
He D; Han H; Fu X; Liu A; Zhan Y; Qiu H; Ma L; Zhang X; Wang X
Can J Diabetes; 2022 Mar; 46(2):150-156. PubMed ID: 35148952
[TBL] [Abstract][Full Text] [Related]
28. Gut microbiota dysbiosis in stable coronary artery disease combined with type 2 diabetes mellitus influences cardiovascular prognosis.
Tian R; Liu H; Feng S; Wang H; Wang Y; Wang Y; Liang L; Xu H; Xing H; Zhang S
Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1454-1466. PubMed ID: 33810955
[TBL] [Abstract][Full Text] [Related]
29. Prebiotic Mannan-Oligosaccharides Augment the Hypoglycemic Effects of Metformin in Correlation with Modulating Gut Microbiota.
Zheng J; Li H; Zhang X; Jiang M; Luo C; Lu Z; Xu Z; Shi J
J Agric Food Chem; 2018 Jun; 66(23):5821-5831. PubMed ID: 29701959
[TBL] [Abstract][Full Text] [Related]
30. Effects of combination treatment with metformin and berberine on hypoglycemic activity and gut microbiota modulation in db/db mice.
Lyu Y; Li D; Yuan X; Li Z; Zhang J; Ming X; Shaw PC; Zhang C; Kong APS; Zuo Z
Phytomedicine; 2022 Jul; 101():154099. PubMed ID: 35489323
[TBL] [Abstract][Full Text] [Related]
31. 16S rRNA Sequencing and Metagenomics Study of Gut Microbiota: Implications of BDB on Type 2 Diabetes Mellitus.
Zhang L; Luo J; Li X; Guo S; Shi D
Mar Drugs; 2020 Sep; 18(9):. PubMed ID: 32957565
[TBL] [Abstract][Full Text] [Related]
32. Host-microbiome interactions in human type 2 diabetes following prebiotic fibre (galacto-oligosaccharide) intake.
Pedersen C; Gallagher E; Horton F; Ellis RJ; Ijaz UZ; Wu H; Jaiyeola E; Diribe O; Duparc T; Cani PD; Gibson GR; Hinton P; Wright J; La Ragione R; Robertson MD
Br J Nutr; 2016 Dec; 116(11):1869-1877. PubMed ID: 27974055
[TBL] [Abstract][Full Text] [Related]
33. Progressive Shifts in the Gut Microbiome Reflect Prediabetes and Diabetes Development in a Treatment-Naive Mexican Cohort.
Diener C; Reyes-Escogido ML; Jimenez-Ceja LM; Matus M; Gomez-Navarro CM; Chu ND; Zhong V; Tejero ME; Alm E; Resendis-Antonio O; Guardado-Mendoza R
Front Endocrinol (Lausanne); 2020; 11():602326. PubMed ID: 33488518
[TBL] [Abstract][Full Text] [Related]
34. Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study.
Palacios T; Vitetta L; Coulson S; Madigan CD; Lam YY; Manuel R; Briskey D; Hendy C; Kim JN; Ishoey T; Soto-Giron MJ; Schott EM; Toledo G; Caterson ID
Nutrients; 2020 Jul; 12(7):. PubMed ID: 32660025
[TBL] [Abstract][Full Text] [Related]
35. Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial.
Lee SE; Choi Y; Jun JE; Lee YB; Jin SM; Hur KY; Ko GP; Lee MK
Diabetes Metab J; 2019 Aug; 43(4):422-431. PubMed ID: 31237126
[TBL] [Abstract][Full Text] [Related]
36. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment.
Gu Y; Wang X; Li J; Zhang Y; Zhong H; Liu R; Zhang D; Feng Q; Xie X; Hong J; Ren H; Liu W; Ma J; Su Q; Zhang H; Yang J; Wang X; Zhao X; Gu W; Bi Y; Peng Y; Xu X; Xia H; Li F; Xu X; Yang H; Xu G; Madsen L; Kristiansen K; Ning G; Wang W
Nat Commun; 2017 Nov; 8(1):1785. PubMed ID: 29176714
[TBL] [Abstract][Full Text] [Related]
37. Pharmacologic and Nonpharmacologic Therapies for the Gut Microbiota in Type 2 Diabetes.
Caesar R
Can J Diabetes; 2019 Apr; 43(3):224-231. PubMed ID: 30929665
[TBL] [Abstract][Full Text] [Related]
38. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
Nunez DJ; Yao X; Lin J; Walker A; Zuo P; Webster L; Krug-Gourley S; Zamek-Gliszczynski MJ; Gillmor DS; Johnson SL
Diabetes Obes Metab; 2016 Jul; 18(7):654-62. PubMed ID: 26939572
[TBL] [Abstract][Full Text] [Related]
39. Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients.
Elbere I; Silamikelis I; Dindune II; Kalnina I; Ustinova M; Zaharenko L; Silamikele L; Rovite V; Gudra D; Konrade I; Sokolovska J; Pirags V; Klovins J
PLoS One; 2020; 15(10):e0241338. PubMed ID: 33125401
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications.
Zhao L; Lou H; Peng Y; Chen S; Zhang Y; Li X
Endocrine; 2019 Dec; 66(3):526-537. PubMed ID: 31591683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
